Login to Your Account



Fruquintinib meets phase III study endpoints in CRC

By Shannon Ellis
Staff Writer

Monday, March 6, 2017

SHANGHAI – Hutchison Medipharma Ltd. announced its first phase III win with fruquintinib, a targeted VEGFR inhibitor studied as a third-line therapy in 416 Chinese patients with colorectal cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription